News

Hosted on MSN7mon
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
On Tuesday, Praxis Precision Medicines Inc. (NASDAQ:PRAX) released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and ...
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
To RSVP and attend the live event, you may click here. A replay of the webinar will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s ...